Article2008

Prolonged-release melatonin for the treatment of insomnia in patients over 55 years

35 citations0/0 files storedExpert Opinion on Investigational Drugs

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Abstract

BACKGROUND: Clinical data show that poor quality, rather than quantity, of sleep corresponds negatively to measures of health, well-being and satisfaction with life. However, until now treatment of insomnia has primarily targeted quantity of sleep. PR (prolonged release)-melatonin offers a new treatment option in insomnia. OBJECTIVES: To provide an overview of PR-melatonin, the first melatonin receptor agonist to be granted marketing authorisation in Europe as monotherapy for the treatment of primary insomnia in patients aged > 55 years. METHODS: Review data published in peer review journals and the EMEA (European Medicines Agency) website. RESULTS/CONCLUSION: PR-melatonin significantly improves morning alertness and quality of sleep compared with placebo. There are no safety concerns.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 35 citations exist upstream.

References

1989The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research 2006Recommendations for a Standard Research Assessment of Insomnia 2005Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits 2007Epidemiology of Insomnia: a Longitudinal Study in a UK Population 2007The Direct and Indirect Costs of Untreated Insomnia in Adults in the United States 1999Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. II.2003Insomnia: Epidemiology, characteristics, and consequences 2007Prolonged‐release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.